Find the right fit for you - faster
Get tailored insights about working at Icagen in one quick step.
Icagen Snapshot
Icagen wants to set the market for ion channel modulators on fire. The development-stage biotech focuses on treatments for epilepsy, asthma, pain, and inflammation by regulating the inflow into cells of such ions as calcium, potassium, and sodium. Icagen's lead candidate, senicapoc for sickle cell disease, died in 2007 following lackluster Phase III clinical trial results. The drug was being developed in a partnership with Johnson & Johnson subsidiary McNeil Consumer & Specialty Pharmaceuticals. Shortly thereafter Icagen announced a deal collaborating with Pfizer on the development of epilepsy and pain treatments. Then, in 2011, the company decided to just go ahead and be acquired by Pfizer.
